Atossa Genetics Receives $6.33 Target Price Amid Mixed Analyst Ratings

Atossa Genetics Inc. has garnered a consensus target price of $6.33 from analysts following its stock, according to a report by Marketbeat.com. The company, which trades on the NASDAQ under the symbol ATOS, is currently rated as a “Hold” by five brokerages covering its shares. Among these firms, two analysts have issued sell recommendations, two have classified the stock as a buy, and one has given it a strong buy rating.

Recent assessments of ATOS have produced varied opinions from financial analysts. On October 8, 2023, Weiss Ratings reaffirmed a “sell (d-)” rating for the company. Shortly thereafter, on October 13, 2023, Zacks Research downgraded Atossa Genetics from a “hold” to a “strong sell” rating. Conversely, on December 8, 2023, Ascendiant Capital Markets raised their target price for Atossa Genetics from $7.75 to $8.00, while assigning a buy rating.

The stock opened at $0.59 on the latest trading day, reflecting a decline of 5.1%. Atossa Genetics currently holds a market capitalization of $76.21 million with a price-to-earnings (P/E) ratio of -2.46. The company’s shares display a fifty-day simple moving average of $0.78 and a 200-day simple moving average of $0.83. Over the past year, Atossa Genetics has experienced a low of $0.55 and a high of $1.29.

In the latest quarterly earnings report released on November 12, 2023, Atossa Genetics reported earnings per share of ($0.07), meeting analysts’ expectations. For the current fiscal year, analysts predict an average earnings per share of ($0.22).

Atossa Genetics, headquartered in Seattle, Washington, is a clinical-stage biotechnology company focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company is dedicated to providing targeted, minimally invasive solutions that enhance early detection, treatment, and prevention for women who are at risk for or diagnosed with breast malignancies. Its product pipeline includes Z-Endoxifen, an oral formulation designed to treat and prevent estrogen receptor-positive breast cancers, particularly among patients with ductal carcinoma in situ or those at high risk of recurrence.

Investors and interested parties can sign up for daily summaries and updates on Atossa Genetics through MarketBeat.com’s newsletter, which provides insights into the latest news and analysts’ ratings for the company and its peers.